Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × epacadostat × 90 days × Clear all
NCT03414229 2026-04-23

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled 11 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡